Teleflex (TFX) risk factors, FY2024 10-K

Risks Relating to our Business and Operations

1. 01We face strong competition. Our failure to successfully develop and market new products could adversely affect our business
2. 02Our customers depend on third party coverage and reimbursements, and the failure of healthcare programs to provide sufficient coverage and reimbursement for our medical products could adversely affect us
3. 03We are subject to extensive government regulation, which may require us to incur significant expenses to ensure compliance. Our failure to comply with those regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows
4. 04We are subject to healthcare fraud and abuse laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition
5. 05We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions, and may experience business disruptions associated with restructuring, facility consolidations, realignment, cost reduction and other strategic initiatives
6. 06Disruptions in sterilization of our products or regulatory initiatives further restricting the use of ethylene oxide in sterilization facilities could adversely affect our results of operations and financial condition
7. 07A significant portion of our U.S. revenues is derived from sales to distributors, and “destocking” activity by these distributors can adversely affect our revenues and results of operations
8. 08Volatility in domestic and global financial markets, including inflation, interest rate fluctuations, and global supply chain disruptions, could adversely impact our results of operations, financial condition and liquidity
9. 09Our strategic initiatives, including acquisitions, may not produce the intended growth in revenue and operating income, which could have a material adverse effect on our operating results
10. 10Our results of operations and financial condition may be adversely affected by public health epidemics or pandemics, as occurred with respect to the recent COVID-19 epidemic and pandemic
11. 11Health care reform may have a material adverse effect on our industry and our business
12. 12We are subject to risks associated with our non-U.S. operations
13. 13Future material impairments to the value of our goodwill or other intangible assets would negatively affect our operating results
14. 14Foreign currency exchange rate, commodity price and interest rate fluctuations may adversely affect our results
15. 15Fluctuations in our effective tax rate and changes to tax laws may adversely affect us
16. 16An interruption in our manufacturing or distribution operations or our supply of raw materials may adversely affect our business
17. 17Our ability to attract, train, develop and retain key employees is important to our success
18. 18Our failure to maintain strong relationships with physicians and other health care professionals could adversely affect us
19. 19Our technology is important to our success, and our failure to protect our intellectual property rights could put us at a competitive disadvantage
20. 20Our products or processes may infringe the intellectual property rights of others, which may cause us to pay unexpected litigation costs or damages or prevent us from selling our products
21. 21Other pending and future litigation may involve significant costs and adversely affect our business
22. 22Disruption of critical information systems or material breaches in the security of our systems may adversely affect our business and customer relationships
23. 23Our operations expose us to the risk of material environmental and health and safety liabilities
24. 24The effects of climate change or legal, regulatory or market measures intended to address climate change could adversely affect our business, results of operations, financial condition and cash flows
25. 25Our workforce covered by collective bargaining and similar agreements could cause interruptions in our provision of products and services
26. 26The proposed separation of our Urology, Acute Care and OEM businesses may not be completed on the terms or timeline currently contemplated, if at all
27. 27We will be exposed to new risks as a result of the proposed separation. The proposed separation may not achieve its anticipated benefits, or our costs may exceed our estimates

Risks Relating to our Financing Arrangements

1. 28As of December 31, 2024, we had total consolidated indebtedness of $1.7 billion
2. 29Our debt agreements impose restrictions on our business, which could prevent us from pursuing business opportunities and taking other desirable corporate actions, and may adversely affect our ability to respond to changes in our business and manage our operations
3. 30Under our cross-currency swap agreements, a meaningful decline in the U.S. dollar to euro exchange rate could have a material adverse effect on our cash flows

Risks Relating to Ownership of our Common Stock

1. 31We may issue additional shares of our common stock or instruments convertible into our common stock, which could cause the price of our common stock to decline
2. 32We may not pay dividends on our common stock in the future
3. 33Certain provisions of our corporate governing documents, Delaware law and our Senior Notes could discourage, delay, or prevent a merger or acquisition